Normal pregnancy is associated with reduced systemic pressor responses to infused angiotensin II (ANG II); furthermore, the uterine vascular bed is even less responsive to vasoconstriction by ANG II than the systemic vasculature overall. The mechanism(s) for this refractoriness remains unknown. To in P and early uterine arteries only; the threshold dose was between 5 X 10-" and 5 X 10-9 M ANG II. This ANG II-induced increase in 6-keto-PGFI. by uterine arteries was inhibited by Saralasin, which by itself had no effect. During pregnancy, the reduced systemic pressor response to ANG II and the even greater refractoriness of the uterine vascular bed may be reflective of vessel production of the potent vasodilator, prostacyclin. Furthermore, in the uterine vasculature, this antagonism may be potentiated by specific ANG II receptor-mediated increases in prostacyclin.
Introduction
Normal pregnancy is associated with the development of relative vascular refractoriness to the systemic pressor effects of infused angiotensin II (ANG II)' in women (1) (2) (3) , sheep (4, 5) , and several other species (6, 7) . This refractoriness is lost in women who develop pregnancy-induced hypertension (preeclampsia), and they become exquisitely sensitive to the pressor effects of infused ANG 11 (3, 8) . The mechanism(s) responsible for the development of this relative vascular refractoriness remains unclear. Elevated concentrations of the vasodilating prostaglandins have been found in the circulation of normal pregnant women and sheep (9-1 1), whereas decreased production rates of the potent vasodilator prostacyclin have been reported in women with pregnancy-induced hypertension (9) . Furthermore, the treatment of normal near-term pregnant women (12) or sheep (13) with prostaglandin synthetase inhibitors has been reported to increase the systemic pressor responses to infused ANG II, while the addition of prostaglandin precursors to the diet of male rats results in diminished vascular responses to either renin or ANG 11 (14) . Thus, it appears that prostaglandins may modify vessel reactivity to infused vasoconstrictors such as ANG II during normal pregnancy.
We have demonstrated that the chronically instrumented sheep may serve as an excellent animal model in which to study the normal cardiovascular changes that occur in pregnancy (5, 15) . In these studies, the uterine vascular bed of late pregnant sheep was even less responsive to infused ANG II than the systemic vascular bed overall (16) (17) (18) . Furthermore, doses ofANG II that did not significantly alter ovine uterine blood flow resulted in decreases in blood flow of 50% or greater to nonreproductive tissues such as the kidney, adrenal gland, and perirenal and greater omental fat (17) . Thus, specific vascular beds respond differently to infused ANG II during normal ovine pregnancy. It is possible that prostaglandins may be important in this differential vascular responsiveness since it has been shown that a high venous-arterial concentration difference of vasodilating prostaglandins exists across the gravid uterus (10) . Terragno et al. ( 19, 20) have reported that bovine mesenteric arteries have the capacity to synthesize prostaglandins, and that the principal prostaglandin produced is prostacyclin. In addition, the uterine (21), renal (22) , and splenic (23) vascular beds have been shown to produce various prostaglandins in response to infused ANG II. Thus, it would appear that during normal pregnancy the systemic vascular refractoriness to ANG II and the even greater refractoriness of the uterine vascular bed to ANG II could be due to increased vessel production ofprostaglandins, specifically prostacyclin. The objectives of the present experiments therefore were to examine in vitro the production ofprostacyclin by ovine uterine and systemic arteries and to determine the effect that ANG II might have on this synthesis.
Methods
Experiment 1. Postpartum ewes were assigned randomly to be killed either on days [1] [2] [3] [4] 20 Ml ofan aspirin (acetylsalicyclic acid) solution (5.0 mg/ml). For nonpregnant vessels the media was completely removed, the chamber refilled, and the vessels retreated with ANG II; a second sample was obtained at the end of the second hour. Tubes were immediately frozen on dry ice and stored at -20°C until the time of assay. Experiment 2. In a second set ofexperiments we sought to determine the role of the ANG II vascular receptors in the ANG lI-induced production of prostacyclin using Saralasin (Saralasin acetate [Sar', Val5, Ala8-angiotensin II], Eaton Laboratories, Norwich, NY), the specific ANG II receptor antagonist. Early (n = 6, 2.2±0.6 d) and late postpartum (n = 5, 13.0±1.0 d) animals were randomly assigned to be killed and the uterine and omental arteries were collected as described above. Incubation chambers were treated with 0, 5 X 10-9 M, 5 X I0O-M, 5 X 10-7 M, or 5 X 10-6 M ANG II as described above, but in the presence or absence of 5 X 1-7 M Saralasin. After 1 h ofincubation the media was completely evacuated from each chamber; the chamber was refilled with KrebsHenseleit, and retreated with ANG II and/or Saralasin; a second sample was collected at the end ofthe second hour of incubation. Samples were immediately frozen and stored at -20°C until the time of radioimmunoassay for prostaglandins. Experiment 3. In this study, seven pregnant sheep were killed at 131±4 d of gestation (term 144±5 d) and the uterine and omental arteries were collected as described above. Incubation chambers were treated with 0, 5 X 10-" M, 5 X 10-10 M, 5 X 10-9 M, and 5 X 10-8 M ANG II in the presence or absence of Saralasin (5 X 10-' M). Additional doses of ANG II comparable to exps. 1 and 2 could not be studied because of the limited number of available incubation chambers. After 1 h of incubation the vessel segments were transferred into another chamber containing Krebs-Henseleit and the drug treatment repeated; another sample was collected at the end of the second hour of incubation. All samples were immediately frozen and stored at -20°C until assayed for prostaglandins.
Radioimmunoassay procedures. Samples ofthe incubate were assayed for the stable metabolite of prostacyclin, 6-keto-prostaglandin F1, (6- keto-PGFI.), by radioimmunoassay using the methods previously described and validated in these laboratories (24) . Briefly, the direct assay procedure used standard (0-500 pg) and unknown quantities of 6-ketoPGFIa mixed in Krebs-Henseleit plus 0.1 M phosphate saline gelatin buffer (1:1) prepared in duplicate 0.2-ml aliquots. Antiserum (0.1 ml, 
Results
Validation. As seen in Fig. 1 , the production of 6-keto-PGF,,a remained constant for both early uterine and omental vessels over a 2-h incubation, averaging 3.93±0.13 and 1.19±0.13 pg/ mg * min, respectively. Therefore, there was no evidence of limited substrate availability in the paradigm used. The addition of aspirin to the incubation media significantly inhibited prostacyclin production by both uterine and omental segments obtained from early postpartum (n = 18) and nonpregnant sheep (n = 11) (Table I) . Additionally, boiling uterine and systemic arteries (n = 12) from early animals decreased prostacyclin production from 163±30 and 60±5.3 to 2.0±0.4 and 1.7±0.6 pg/ mg* h, respectively (P < 0.01). Thus, prostaglandin production was de novo. It is also of note (Table I) Table II . In the absence ofANG II, early uterine and omental arteries produced substantially more 6-keto-PGFia than comparable vessels from late postpartum or nonpregnant sheep (P < 0.05). Furthermore, the amount of 6-keto-PGF1, produced by control early uterine arteries was nearly twice that produced by the early omental vessels, 165±34 vs. 79±22 pg/ mg * h (P < 0.01), respectively; this difference in vessel production of 6-keto-PGF1, was not found in arteries obtained from nonpregnant and late postpartum ewes. The addition of various concentrations of ANG II to the media resulted in increased 6-keto-PGFIa production only by early uterine arteries (P < 0.05); however, no dose-response was observed over the dose range studied and a mean increase to 255±24 pg/mg. h was obtained.
The addition of aspirin (50 ,gg/ml) inhibited the ANG II-induced rise in 6-keto-PGFi,, a reflection of the inhibition of the basal production of prostacyclin. Experiment 2. As in exp. 1, in the absence of ANG II, uterine arteries obtained from early postpartum ewes produced greater amounts of 6-keto-PGFia than vessels obtained from late postpartum animals (Table III) . Furthermore, as noted above, ANG II specifically augmented the synthesis of prostacyclin by early uterine arteries (P < 0.05) and no dose-response was detected.
The addition of Saralasin (5 X l0-7 M) to the incubate had no affect on the basal production rate of prostacyclin; however, the specific increase in 6-keto-PGF1,,, production by early uterine arteries treated with ANG II was inhibited by Saralasin (P < 0.05). Prostacyclin production by late postpartum uterine arteries (Table III) , as well as early or late omental arteries (Table  IV) , was unaffected by the addition of either ANG II or ANG II plus Saralasin. Again, note in Table IV that early omental arteries produced more 6-keto-PGFI,, than late postpartum vessels. Experiment 3. When vessels obtained from near-term pregnant sheep were examined (Table V) , the basal production of 6-keto-PGFI,, by uterine arteries was nearly fourfold greater than that by systemic arteries (P < 0.01). In an attempt to define a dose-response to ANG II, the minimum dose used in these studies was two orders of a magnitude lower (5 X 101-M vs. 5 X 10-9 M) than that employed in exps. I and 2. As with early uterine arteries, ANG II specifically augmented prostacyclin synthesis by uterine arteries; however, this occurred in a dosedependent manner, with a threshold dose between 5 X 10-1 M and 5 X 10-9 M ANG II. Although the addition of Saralasin (5 X l0-7 M) to the incubation media did not alter basal synthesis of prostacyclin, the ANG II-induced increases in 6-keto-PGFIa production by uterine arteries were inhibited (P < 0.05). The production of 6-keto-PGFIa by omental arteries tended to increase at 5 X 10-9 M and 5 X 10-8 M ANG II; this, however, was not significant. There was no effect of Saralasin or ANG II plus Saralasin on omental arteries.
A comparison ofthe basal production rates of 6-keto-PGF1a obtained in exps. 1-3 is presented in Fig. 2 (26) , differences in cardiac responses between pregnant and nonpregnant subjects (27) , an effect of the steroid hormones of pregnancy (7, 28) , alterations in vessel wall mechanics, and increased production of vasodilating prostaglandins (9) (10) (11) (12) (13) (29, 30) . We also have shown that neither changes in cardiac responses (31) nor alterations in the metabolic clearance rate of ANG 11 (32) appear to be important. Therefore, at least two possible considerations remain, i.e., alterations in the vessel wall itself, which may be related to the elevation in steroid hormones found in normal pregnancy, or production of a prostaglandin(s) that might serve to antagonize the vasoconstricting properties of infused ANG II (12, 13) .
Little is presently known about changes in the mechanics of the vessel; however, evidence for a role for prostaglandins in the development of vascular refractoriness in pregnancy is obtained from several observations, e.g., high circulating levels and an increased production rate of vasodilating prostaglandins in both normal ovine and human pregnancy (9-1 1), and significantly enhanced systemic pressor responses to infused ANG II in pregnant women and sheep after pretreatment with either aspirin or indomethacin, respectively (12, 13) . Therefore, we chose to examine the in vitro production of prostaglandins, especially prostacyclin, in arteries obtained from nonpregnant and pregnant sheep and from animals in the early and late peurperium.
It is clear from the results obtained that arteries from the uterine vasculature and greater omentum of sheep have the capacity to release newly synthesized prostaglandins from endogenous substrate stores, and that this synthesis is not substrate limited for up to 2 h of incubation. Furthermore, the primary prostaglandin produced by these vessels was 6-keto-PGFa, the stable metabolite of prostacyclin, since values for PGE2 and PGF2a were at or below the sensitivity of our assays. The observation that prostacyclin is the primary prostaglandin produced by these vessels is consistent with that of Terragno et al. (20) , who reported similar results in studies of bovine mesenteric vessels.
Although omental arteries from all animals produced 6-keto- women with pregnancy-induced hypertension have been reported to have decreased production of prostacyclin (9) . In considering any cardiovascular changes that occur in pregnancy, it is important to examine the uterine circulation, since alterations in this vascular bed are peculiar to pregnancy. We have demonstrated in unanesthetized, near-term pregnant sheep that although ANG II acts only as a vasoconstrictor in this vascular bed, as in other vascular beds (16, 17, 36) , the uterine vasculature is even less responsive to infused ANG II than the systemic vasculature overall (16) (17) (18) . Because of this differential sensitivity to the vasoconstricting effects of ANG II, uterine blood flow may be observed to rise during the systemic infusion of physiologic doses ofANG II, a finding that has caused some to report that this vasoconstrictor might be a uterine vasodilator (21, 37) . However, this increase in uterine blood flow is reflective ofthe substantial rise in perfusion pressure at a time when the increase in uterine vascular resistance is significantly less than that of systemic vascular resistance, thus reflecting the interaction between perfusion pressure, vascular resistance, and blood flow to this vascular bed.
To determine whether vessel production of prostaglandins, specifically prostacyclin, might be important in the even greater refractoriness of the uterine vascular bed to infused ANG II than the systemic vasculature, we also studied uterine arteries obtained from nonpregnant, pregnant, early postpartum, and late postpartum sheep. Not only did pregnant and early postpartum uterine arteries produce 5-to 10-fold more 6-keto-PGF1a than similar vessels obtained from late postpartum and nonpregn~ant sheep, but they also produced substantially more than that by omental (systemic) arteries from all animals. This difference in the ability to produce prostacyclin could explain the differential sensitivity to infused ANG II previously observed between the uterine and systemic vascular beds (16) (17) (18) . Moreover, we also observed that when ANG II was added to the incubate of uterine arteries from pregnant and early postpartum sheep, there was a nearly 100% increase in 6-keto-PGFIa¢ production that was specific to these vessels and mediated through the ANGII receptor. Thus, it is even more likely that the substantial uterine refractoriness to infused ANG II is reflective of not only the greater basal production rate of prostacyclin, but also the ANG lI-induced increases in prostacyclin. Similar ANG II-stimulated increases in prostaglandin production have been shown to occur in the kidney (22, 38) and spleen (23) , and as in the present study, this was blocked by specific ANGII receptor antagonists. Satoh et al. (38) have reported that a differential effect of ANGII, similar to that reported in the present investigation, exists for renal and femoral arteries, and that this ANG II receptor-mediated phenomenon in renal arteries is associated with the action of phospholipase A2.
Although we could not demonstrate a dose-response for the ANG II-induced increases in 6-keto-PGFIa by uterine arteries from early postpartum sheep, a dose-response was observed when subsequent studies were performed with arteries from pregnant sheep using doses of ANG II two orders of magnitude lower. In these studies, maximum stimulation of vascular production of 6-keto-PGFi,, occurred at 5 X l0-9 M ANGII, and no further increases occurred at higher doses. The presence of a dose-response is consistent with the observations of others studying renal arteries (38). It is noteworthy that although the relative ANG II-induced increase in 6-keto-PGF1a production by uterine arteries from pregnant and early postpartum ewes was not different, -100%, the absolute increase by pregnant arteries was three times that of early postpartum vessels, 350±81 vs. 1 13±26 pg/mg-h, respectively. This difference likely reflects the ability of the pregnant uterine arteries to produce greater amounts of prostacyclin; however, an explanation for this is not yet apparent.
In these studies, we also have demonstrated that systemic and uterine arterial production of 6-keto-PGFIa rises 3-and 10- fold, respectively, from the nonpregnant state to near-term pregnancy, and that it gradually falls during the puerperium, attaining production rates similar to that seen in vessels from nonpregnant animals by 2 wk postpartum. Although quantitatively different, pregnancy also has been shown to modify the effects ofestrogeninduced vasodilation (39, 40) ; that is, estrogen-induced vaso-dilation of the uterine vasculature is maximum in nonpregnant sheep, progressively decreases during pregnancy, and gradually returns to nonpregnant responses by 10-14 d postpartum. We also have demonstrated in the present studies that the ANG IIinduced increase in uterine arterial production of 6-keto-PGFia is absent in nonpregnant and late postpartum uterine vessels, but present in vessels from near-term pregnant sheep and within 1 to 4 d after parturition. These observations are supportive of the view that some factor peculiar to pregnancy, likely a hormone, is responsible for the pattern ofthese vascular alterations. In this regard, Dadak et al. (41) have suggested that a prostacyclin stimulating factor is present in the plasma ofpregnant and postpartum women. It is possible that this factor may be estrogen, since prostacyclin production by vascular endothelium (42) and smooth muscle (43, 44) may be stimulated by this steroid hormone. Moreover, we have shown that estrogenization of nonpregnant castrated sheep will result in refractoriness to the pressor effects of ANG 11 (28) .
From the results obtained in these studies, it is reasonable to suggest that prostacyclin production by both uterine and omental arteries may serve to antagonize the vasoconstrictor responses to infused ANG II in normal pregnancy. Moreover, the greater refractoriness to infused ANG II of the uterine vascular bed as compared with the systemic vasculature overall very likely reflects not only an increased capacity of the uterine arteries to produce prostacyclin, but also the ANG II receptormediated increases in prostacyclin production. This difference between the uterine and systemic vascular beds could be reflective ofan adaptative mechanism that is necessary for the maintenance of uteroplacental perfusion and fetal well being, since ANG II normally increases in pregnancy and likely increases even further, although intermittently, during the course of normal daily activities.
